| Literature DB >> 26837242 |
Tinashe B Ruwona1, Haiyue Xu1, Junwei Li2, Diana Diaz-Arévalo2, Amit Kumar1, Mingtao Zeng2, Zhengrong Cui1.
Abstract
Botulinum neurotoxin (BoNT) is a lethal neurotoxin, for which there is currently not an approved vaccine. Recent efforts in developing vaccine candidates against botulism have been directed at the heavy chain fragment of BoNT, because antibodies against this region have been shown to prevent BoNT from binding to its receptor and thus to nerve cell surface, offering protection against BoNT intoxication. In the present study, it was shown that immunization with plasmid DNA that encodes the 50 KDa C-terminal fragment of the heavy chain of BoNT serotype C (i.e., BoNT/C-Hc50) and is carried by cationic poly (lactic-co-glycolic) acid (PLGA) nanoparticles induces stronger BoNT/C-specific antibody responses, as compared to immunization with the plasmid alone. Importantly, the antibodies have BoNT/C-neutralizing activity, protecting the immunized mice from a lethal dose of BoNT/C challenge. A plasmid DNA vaccine encoding the Hc50 fragments of BoNT serotypes that cause human botulism may represent a viable vaccine candidate for protecting against botulinum neurotoxin intoxication.Entities:
Keywords: PLGA nanoparticles; antibody responses; botulinum neurotoxin; mouse survival
Mesh:
Substances:
Year: 2016 PMID: 26837242 PMCID: PMC4963044 DOI: 10.1080/21645515.2015.1122147
Source DB: PubMed Journal: Hum Vaccin Immunother ISSN: 2164-5515 Impact factor: 3.452